History | Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

Guidance published

Equality impact assessment 4 and 5 (PDF 125 KB)

Published:

23 November 2022
Committee member list (PDF 89 KB)

Published:

23 November 2022
Consultation comments and responses (PDF 1.87 MB)

Published:

23 November 2022
Addendum Acknowledgements (PDF 193 KB)

Published:

23 November 2022

Committee list updated

Committee member list (PDF 89 KB)

Published:

11 May 2021

Draft guidance consultation

Draft guidance consultation
Evidence review L_int rebleed (PDF 2.32 MB)

Published:

12 February 2021
Evidence review M_timing int rebleed (PDF 1.8 MB)

Published:

12 February 2021
Evidence review N_Risk of subsequent (PDF 1.72 MB)

Published:

12 February 2021
Evidence review O_imaging strategies follow up (PDF 1.06 MB)

Published:

12 February 2021
Evidence review P_non-culprit (PDF 2.59 MB)

Published:

12 February 2021
Evidence review Q_long-term medication reduce risk (PDF 1.29 MB)

Published:

12 February 2021
Evidence review R_long-term medication consequences (PDF 1.04 MB)

Published:

12 February 2021
Evidence review S_Patient_info (PDF 928 KB)

Published:

12 February 2021
Evidence review T_investigate relatives (PDF 1.09 MB)

Published:

12 February 2021
Evidence review A_Signs and symptoms (PDF 1.56 MB)

Published:

12 February 2021
Evidence review B_diagnostic accuracy and strategies (PDF 3.38 MB)

Published:

12 February 2021
Evidence review C_severity scoring (PDF 3.35 MB)

Published:

12 February 2021
Evidence review D_medical management (PDF 3.75 MB)

Published:

12 February 2021
Evidence review E_monitoring for deterioration (PDF 1.22 MB)

Published:

12 February 2021
Evidence review F_managing DCI (PDF 1.46 MB)

Published:

12 February 2021
Evidence review G_detecting hydrocephalus (PDF 861 KB)

Published:

12 February 2021
Evidence review H_managing hydrocephalus (PDF 1.25 MB)

Published:

12 February 2021
Evidence review I_detecting ICH (PDF 1.29 MB)

Published:

12 February 2021
Evidence review J_managing ICH (PDF 1.2 MB)

Published:

12 February 2021
Evidence review K_diagnostic imaging strategies (PDF 3.76 MB)

Published:

12 February 2021
Committee member list (PDF 205 KB)

Published:

12 February 2021
Draft guideline (PDF 578 KB)

Published:

12 February 2021
Supporting documentation - Methods (PDF 1.01 MB)

Published:

12 February 2021
Comments form (MSWord 37 KB)

Published:

12 February 2021
Equality impact assessment - Section 3 (PDF 133 KB)

Published:

12 February 2021

Stakeholder list updated

Stakeholder list (PDF 133 KB)

Published:

22 November 2022

Pre-consultation documents released

Economic plan (PDF 23 KB)

Published:

01 February 2021
Review questions (PDF 107 KB)

Published:

01 February 2021
Search strategies (PDF 1.86 MB)

Published:

01 February 2021

Committee meetings

Committee meeting
Minutes 1 & 2 (PDF 228 KB)

Published:

16 January 2019
Minutes 14 Jan 2019 (PDF 199 KB)

Published:

12 February 2019
Minutes 11 Feb 2019 (PDF 203 KB)

Published:

21 May 2019
Minutes 16 & 17 May 2019 (PDF 206 KB)

Published:

30 July 2019
Minutes 28 June 2019 (PDF 203 KB)

Published:

01 October 2019
Minutes 16&17 September 2019 (PDF 214 KB)

Published:

09 December 2019
Minutes 08 Nov 2019 (PDF 191 KB)

Published:

15 January 2020
Minutes 13 January 2020 (PDF 196 KB)

Published:

10 March 2020
Minutes (PDF 135 KB)

Published:

06 January 2021
Minutes - GC15 (PDF 123 KB)

Published:

21 April 2021
Minutes - 16 (PDF 120 KB)

Published:

18 August 2021

Declaration of interests

Register of interests (PDF 302 KB)

Published:

22 November 2022

Scope published

Final scope (PDF 291 KB)

Published:

30 October 2018
Consultation comments and responses (PDF 649 KB)

Published:

30 October 2018
Equality impact assessment (PDF 287 KB)

Published:

30 October 2018

Draft scope consultation

Draft scope consultation
Comments form (MSWord 31 KB)

Published:

22 August 2018
Draft scope (PDF 326 KB)

Published:

22 August 2018
Stakeholder list (PDF 42 KB)

Published:

22 August 2018
Equality impact assessment (PDF 209 KB)

Published:

22 August 2018

Scoping workshop

Workshop notes (PDF 412 KB)

Published:

24 May 2019